

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |   |
|---|-----------|---|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>A61K 31/715, 47/36, 47/48</b>  | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 97/25051</b><br><b>(43) International Publication Date:</b> 17 July 1997 (17.07.97)   |
| <b>(21) International Application Number:</b> PCT/CA97/00007<br><b>(22) International Filing Date:</b> 8 January 1997 (08.01.97)<br><br><b>(30) Priority Data:</b><br>2,167,044 11 January 1996 (11.01.96) CA<br>2,193,921 24 December 1996 (24.12.96) CA<br><br><b>(71) Applicant (for all designated States except US):</b> HYAL PHARMACEUTICAL CORPORATION [CA/CA]; 2425 Skymark Avenue, Mississauga, Ontario L4W 4Y6 (CA).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> TURLEY, Eva, Anne [CA/CA]; Grand Harbour, Apartment 107, 2287 Lakeshore Boulevard West, Toronto, Ontario M8V 3Y1 (CA). ASCU-LAI, Samuel, Simon [US/CA]; Apartment TH13, 53 McCaul Street, Toronto, Ontario M6M 2B6 (CA).<br><br><b>(74) Agent:</b> HUGHES, ETIGSON; Suite 200, 175 Commerce Valley Drive West, Thornhill, Ontario L3T 7P6 (CA).           |           | <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> ORAL ADMINISTRATION OF EFFECTIVE AMOUNTS OF FORMS OF HYALURONIC ACID<br><br><b>(57) Abstract</b><br><br>This invention relates to the oral administration of forms of hyaluronic acid (for example hyaluronan (hyaluronic acid) and pharmaceutically acceptable salts thereof such as sodium hyaluronate), and orally administrable dosage forms containing forms of hyaluronic acid, for the prevention and/or treatment of diseases and/or conditions such as the prevention of restenosis and the treatment of an infarct (heart attack) or a stroke. The oral administration and the orally administered dosage forms may also include therapeutic agents and/or medicines which may be administered orally for the treatment and/or prevention of the diseases and/or conditions with the forms of hyaluronic acid (hyaluronan) previously described. |           |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |                          |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia                  | GB | United Kingdom                           | MW | Malawi                   |
| AT | Austria                  | GE | Georgia                                  | MX | Mexico                   |
| AU | Australia                | GN | Guinea                                   | NE | Niger                    |
| BB | Barbados                 | GR | Greece                                   | NL | Netherlands              |
| BE | Belgium                  | HU | Hungary                                  | NO | Norway                   |
| BF | Burkina Faso             | IE | Ireland                                  | NZ | New Zealand              |
| BG | Bulgaria                 | IT | Italy                                    | PL | Poland                   |
| BJ | Benin                    | JP | Japan                                    | PT | Portugal                 |
| BR | Brazil                   | KE | Kenya                                    | RO | Romania                  |
| BY | Belarus                  | KG | Kyrgyzstan                               | RU | Russian Federation       |
| CA | Canada                   | KP | Democratic People's Republic<br>of Korea | SD | Sudan                    |
| CF | Central African Republic | KR | Republic of Korea                        | SE | Sweden                   |
| CG | Congo                    | KZ | Kazakhstan                               | SG | Singapore                |
| CH | Switzerland              | LI | Liechtenstein                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LK | Sri Lanka                                | SK | Slovakia                 |
| CM | Cameroon                 | LR | Liberia                                  | SN | Senegal                  |
| CN | China                    | LT | Lithuania                                | SZ | Swaziland                |
| CS | Czechoslovakia           | LU | Luxembourg                               | TD | Chad                     |
| CZ | Czech Republic           | LV | Latvia                                   | TG | Togo                     |
| DE | Germany                  | MC | Monaco                                   | TJ | Tajikistan               |
| DK | Denmark                  | MD | Republic of Moldova                      | TT | Trinidad and Tobago      |
| EE | Estonia                  | MG | Madagascar                               | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                     | UG | Uganda                   |
| FI | Finland                  | MN | Mongolia                                 | US | United States of America |
| FR | France                   | MR | Mauritania                               | UZ | Uzbekistan               |
| GA | Gabon                    |    |  | VN | Viet Nam                 |

**TITLE OF INVENTION**

Oral Administration of Effective Amounts of Forms of Hyaluronic Acid

**FIELD OF INVENTION**

5           This invention relates to the oral administration of forms of hyaluronic acid (for example hyaluronan (hyaluronic acid) and pharmaceutically acceptable salts thereof such as sodium hyaluronate), and orally administrable dosage forms containing forms of hyaluronic acid, for the prevention and/or treatment of diseases and/or conditions  
10 such as the prevention of restenosis and the treatment of an infarct (heart attack) or a stroke. The oral administration and the orally administered dosage forms may also include therapeutic agents and/or medicines which may be administered orally for the treatment and/or prevention of the diseases and/or conditions with the forms of hyaluronic acid  
15 (hyaluronan).

**BACKGROUND OF THE INVENTION**

          In International Publication WO95/26193 (Application PCT/CA94/00188), hyaluronic acid and/or pharmaceutically acceptable salts thereof are administered to prevent restenosis of the arterial walls  
20 when the artery walls are traumatized by for example balloon angioplasty.

          Generally a newborn's arteries each consist of the outer adventitia and inner intima. The inner surface of the intima presents an elastic lamina. As the newborn grows into an adult human, a neointima (made of migrating smooth muscle cells, leucocytes (macrophages) and fat  
25 deposited in the leucocytes (macrophages)(in foamy cells)), develops radially inwardly of the intima, thus narrowing or constricting the opening in the artery (stenosis). This narrowing or constriction reduces blood flow. The development of the neointima depends on the human's diet, physical conditioning and physical and genetic make-up.

30           In some people, the size of the neointima has substantially constricted the blood flow through the artery, jeopardizing the human's life. In an attempt to reduce/alleviate the effects of the size of the neointima and its affects on the human, balloon angioplasty is performed reducing the radial inward extent of the neointima. However in a  
35 substantial number of the humans receiving this procedure, restenosis of the artery occurs by migration of the smooth muscle cells to, and

concentration of leucocytes carrying fat deposits at, the place of the balloon angioplasty thus increasing the radial inward extent of the neointima.

The teachings of publication WO95/26193 provide a procedure for preventing restenosis using forms of hyaluronic acid administered before, during and/or after the balloon angioplasty procedure. Suitable amounts may be administered intravenously, by injection, or subcutaneously. The form of hyaluronic acid preferably had a molecular weight of less than 750,000 daltons and in one embodiment a concentration of about 2% by weight in sterile water. Effective amounts of the form of hyaluronic acid provided in each dosage administered were from about 10 mg/70 kg human to in excess of 3000 mg/70 kg person, prior to, during and/or after the angioplasty procedure. The oral route was not given as one of the preferred routes. The reason is that persons skilled in the art generally believe that oral administration of the form of hyaluronic acid will not at least for small amounts pass the form of hyaluronic acid into the blood system from the stomach. Such persons believe that a substantial portion of any orally administered form of hyaluronan will be digested, degraded or disassociated into its smaller sugar components in the stomach by the stomach acid before a substantial amount of the form of hyaluronan (greater than K (1000) daltons) can enter the blood system. Thus according to the beliefs of persons skilled in the art, very large dosage amounts of the form of hyaluronan would have to be administered orally for oral delivery to be effective, and even then consider it unlikely to escape the stomach as intact high molecular weight HA.

Publication WO91/04058 (Application PCT/CA90/00306) teaches the use of a minimum amount of 10mg/70 kg person of a form of hyaluronan up to in excess of 3000 mg/70 kg person to transport medicines and/or therapeutic agents to the site in the human body in need of the treatment, with preferred amounts exceeding 50mg/70kg person to about 350 mg/70 kg person [Page 26, lines 32-37]. At page 18, reference is made to the proposed routes of administration. One of the routes proposed to be used is by oral administration [Page 18, line 5]. However not one of the specific examples in the document, provides specifics using the oral route. At that time oral administration was thought not to be that efficient. While the oral route may have been

proposed, persons skilled in the art would believe much of the administered form of hyaluronan would not pass intact into the blood stream. Therefore persons skilled in the art would prefer the other routes for example, intravenous and direct injection when employing the  
5 teachings of the document.

Hence Applicants herein believe that oral administration of forms of hyaluronan would not be preferred by persons skilled in the art or in fact be used because to their minds there are better alternate routes. For example the routes of administration of the hyaluronic acid as taught  
10 by U.S. Patent 4,808,576 are intramuscular, intravenous, subcutaneous and topical (Column 3, lines 17-18). No teaching of oral administration of hyaluronic acid is proposed as it was believed at that time (even to the present date) that oral administration would not be as good a route.

Thus Applicants believe that the preferred routes of  
15 administration to persons skilled in the art are systemic (intravenous, direct injection), subcutaneous and most recently topical. However systemic administration requires hospital or medical clinic time for administration - a costly procedure even under "out-patient" treatment conditions. If the patient in the hospital were to be treated by intravenous  
20 administration or by subcutaneous injection over for example 3-5 days, the costs can be substantial. For many conditions, topical treatment is not appropriate.

It is therefore an object of this invention to provide for the prevention and/or treatment of diseases and/or conditions by the oral  
25 administration of forms of hyaluronic acid (hyaluronan).

It is a still further object of the invention to provide orally administrable dosages containing forms of hyaluronan which allow the orally administrable form of intact hyaluronan in the stomach prior to passage into the blood stream, in a biologically active form (35,000 daltons  
30 to 2,000,000 daltons) determined by the Dextran Standard. (The conversion factor from the newer Dextran Standard to the older Protein Standard on which earlier filed applications were based, is in the order of about 3.3. The molecular weight determined under the newer Dextran Standard must be divided by 3.3 to determine the molecular weight under  
35 the older Protein Standard. Thus, the above molecular weights would be between about 11,000 daltons to about 600,000 K. daltons.)

It is a further object of the invention to provide dosages containing forms of hyaluronan for oral administration.

Further and other objects of the invention will be realized by those skilled in the art from the following summary of the invention and  
5 detailed discussion of embodiment thereof.

### SUMMARY OF THE INVENTION

In the development of this invention, the inventors have discovered:

- 10 (a) that unexpectedly, hyaluronan when administered orally can be effective to treat and/or prevent a condition and/or disease of a human, such as prevent restenosis;
- (b) that unexpectedly "more" hyaluronan is not necessarily better and that unexpectedly "less" hyaluronan may be better  
15 (for example dosage amounts between about 3 mg/kg of body weight of a human to about 100 mg/kg of a human of a form of hyaluronan and preferably between about between 3 mg/kg to about 30 mg/kg of a human and more preferably between about 3 mg/kg to about 10mg/kg for example to prevent restenosis, is preferred (the effect of the  
20 administered dosage amounts of the form of hyaluronan thereby being "phasic")) ; and
- (c) that unexpected molecular weight distributions of the form of hyaluronan, ranging from 30,000 to greater than 70,000 daltons (determined by the well known Protein Standard),  
25 and in the human between 30,000 to 2,000,000 daltons using the Dextran Standard (which is believed to be more accurate) are the molecular weights of the form of hyaluronan that appear in plasma after administered orally (for example comprising a solution of 2% sodium hyaluronate by weight in sterile water) preventing minimal degradation by the  
30 human body when given orally, compared to subcutaneous or intravenous administration. [Once again, conversion of the molecular weight determined by the Dextran Standard must be divided by the conversion factor which factor is in the order of about 3.3. Thus the molecular weights of 30,000  
35 to 2,000,000 daltons using the Dextran Standard correspond

from about 9,000 daltons to about 600,000 daltons in the older Protein Standard.]

Therefore new dosages for administration to humans, each dosage containing forms of hyaluronan which the human body can easily use (by delivering the form of hyaluronan directly from the stomach into the blood stream) may comprise in suitable form (preferably liquid form) for oral administration in a suitable excipient (for example sterile water), at least one of the following:

(i) between about 3 mg of the form of hyaluronan/kg to about 100 mg of the form of hyaluronan/kg of body weight of the human taking the oral dose form, in the oral dosage form (preferably between about 3mg/kg and about 30mg/kg of the human of the form of hyaluron and more preferably the amount of the form of hyaluronan is between about 3mg/kg to about 10mg/kg of the body weight of the human taking the oral dosage) and

(ii) the form of hyaluronan in the orally administrable dosage form having a mean average molecular weight distribution in the range selected from the following group of ranges,

(a) between about 30,000 to 2,000,000 daltons is detected by Dextran Standards (which corresponds to between about 9,000 daltons and about 600,000 daltons delivered by the Protein Standard using the conversion factor of about 3.3), and

(b) about 30,000 to greater than 70,000 daltons as detected by the Protein Standards.

(for example as a 2% by weight solution of hyaluronan in sterile water).

Therefore new methods of treatment and/or prevention of a disease and/or condition, for example prevention of restenosis, is provided comprising orally administering an effective amount of an orally administrable pharmaceutical dosage form comprising the form of hyaluronan for such period of time as required (including any



maintenance therapy). For example for the prevention of restenosis the oral administration of a dosage according to the invention may take place before, during and/or after balloon angioplasty. The dosage is constituted according to the above new dosages. Thereafter the oral administration of the oral dosages takes place as needed (for example to prevent restenosis after balloon angioplasty, oral administration may take place for a period of 3-5 days after the balloon angioplasty procedure as maintenance therapy). This administration can be carried out by patients at home simply following their doctors' instructions by taking their oral dosages.

10           The form of hyaluronan may comprise hyaluronic acid and/or pharmaceutically acceptable salts thereof, for example, sodium hyaluronate.

          Where the form of hyaluronic acid used in the oral dosage form does not have a molecular weight in the ranges specified above in subparagraph (ii) (a), (b) or (c), the form of hyaluronan preferably has a molecular weight less than 750,000 daltons (Protein Standard), for example 400,000 daltons (Protein Standard) in the amounts specified in subparagraph (i) above.

          One form of hyaluronic acid and/or pharmaceutically acceptable salts thereof suitable for use is a fraction supplied by Hyal Pharmaceutical Corporation (Applicant herein). One such amount is a 15 ml vial of Sodium hyaluronate 20mg/ml (300mg/vial - Lot 2F3). The sodium hyaluronate fraction is a 2% solution with a mean average molecular weight distribution of about 225,000 daltons (Protein Standard). The amount also contains water q.s. which is triple distilled and sterile in accordance with the U.S.P. for injection formulations. The vials of hyaluronic acid and/or pharmaceutically acceptable salts thereof may be carried in a Type 1 borosilicate glass vial closed by a butyl stopper which does not react with the contents of the vial.

30           Many forms of hyaluronan may be suitable for use herein. Particularly, molecular weights of forms of hyaluronan between about 150,000 daltons (Protein Standard) and about 750,000 daltons (Protein Standard) in sterile water prepared having a viscosity for intravenous administration are suitable.

One specific form of pharmaceutical grade is a 1% sterile sodium hyaluronate solution (50 ml vials) provided by Hyal Pharmaceutical Corporation which has the following characteristics:

|    | <u>Tests</u>                                   | <u>Specifications</u>   |
|----|--|---|
| 5  | 1. Container Description                       | 1 50 mL Flint glass vial with a red or gray rubber stopper and an aluminum seal, 20 mm in size. |
| 10 | 2. Product Description                         | A clear, colourless, odourless, transparent, slightly viscous liquid.                           |
|    | 3. Fill Volume                                 | 50.0 to 52.0 mL   |
|    | 4. pH  | 5.0 to 7.0 at 25 degrees C.   |
|    | 5. Specific Gravity                            | 0.990 to 1.010 at 25 degrees C.   |
| 15 | 6. Intrinsic Viscosity                         | 4.5 to 11.0 dL/g  |
|    | 7. Molecular Weight                            | 178,000 to 562,000 daltons  |
|    | 8. Sodium Hyaluronate Assay and Identification | 9.0 to 11.0 mg/mL. Positive   |
| 20 | 9. Particulate Matter                          | No visible Particulate Matter   |
|    | 10. Sterility                                  | Meets Requirements for Sterility, USP 23  |
|    | 11. Bacterial Endotoxins (LAL)                 | Meets Requirements for Bacterial Endotoxins, USP 23.  |

25 This pharmaceutical grade 1% sterile solution of hyaluronan may be made from granules/powder having the following characteristics:

|    | <u>Tests</u>                    | <u>Specifications</u>                                 |
|----|---------------------------------|---|
|    | 1. Description                  | White or cream-coloured granules or powder, odourless |
| 30 | 2. Identification (IR Spectrum) | Must conform with the Reference Standard Spectrum.    |
|    | 3. pH (1% Solution)             | Between 5.0 and 7.0 at 25 degrees C.                  |
|    | 4. Loss on Drying               | NMT 10.0% at 102 degrees C. for 6 hours.              |
|    | 5. Residue on Ignition          | Between 15.0 and 19.0%.                               |
| 35 | 6. Protein Content              | NMT 0.10%   |

|    |  |  |
|----|--|--|
|    | 7. Heavy Metals  | NMT 20 ppm (as per USP 23 p. 1727).  |
|    | 8. Arsenic   | NMT 2 ppm (as per USP 23, p. 1724).  |
| 5  | 9. Residual Solvents   | a) Acetone: NMT 0.1%<br>b) Ethanol: NMT 2.0%<br>c) Formaldehyde: NMT 100 ppm |
|    | 10. Sodium Hyaluronate Assay                                   | 97.0 to 102.0% (dried basis)   |
| 10 | 11. Intrinsic Viscosity  | Between 10.0 to 14.5 deciliters per gram.                                    |
|    | 12. Molecular Weight<br>(calculated using the Laurent Formula) | Between 500,000 to 800,000 daltons<br>(based on intrinsic viscosity).        |
| 15 | 13. Total Aerobic Microbial Count                              | NMT 50 microorganism/gram (as per USP 23, p. 1684).                          |
|    | 14. Test for Escherichia coli                                  | Escherichia coli is absent (as per USP 23, p. 1685).                         |
|    | 15. Yeasts & Molds   | NMT 50 microorganisms/gram (as per USP 23, p. 1686).                         |
| 20 | 16. Endotoxins (LAL)   | NMT 0.07 EU/mg (as per USP 23, p. 1696).                                     |

A topical grade of hyaluronan (which may be sterilized) may, in certain circumstances be suitable and may be made from the following granules/powder which have the following characteristics:

|    |                                 |   |
|----|---------------------------------|---|
| 25 | <b><u>Tests</u></b>             | <b><u>Specifications</u></b>                          |
|    | 1. Description                  | White or cream-coloured granules or powder, odourless |
|    | 2. Identification (IR Spectrum) | Must conform to the Reference Standard Spectrum.      |
| 30 | 3. pH (1% Solution)             | Between 6.0 and 8.0 at 25 degrees C.                  |
|    | 4. Loss on Drying               | NMT 10.0% at 102 degrees C. for 6 hours.              |
|    | 5. Residue on Ignition          | Between 15.0 and 19.0%                                |
|    | 6. Protein Content              | NMT 0.40%   |
| 35 | 7. Heavy Metals                 | NMT 20 ppm (as per USP 23 p. 1727).                   |

|    |  |  |
|----|--|--|
|    | 8. Arsenic                             | NMT 2 ppm (as per USP 23, p. 1724).                        |
|    | 9. Residual Solvents                   | a) Acetone: NMT 0.1%                                       |
| 5  |  | b) Ethanol: NMT 2.0%                                       |
|    |  | c) Formaldehyde: NMT 100 ppm                               |
|    | 10. Sodium Hyaluronate Assay           | 97.0 to 102.0% (dried basis)                               |
|    | 11. Intrinsic Viscosity                | Between 11.5 to 14.5 deciliters per gram.                  |
| 10 | 12. Molecular Weight                   | Between 600,000 to 800,000 daltons (Protein Standard)      |
|    | (calculated using the Laurent Formula) | (based on intrinsic viscosity).                            |
|    | 13. Total Aerobic Microbial Count      | NMT 100 microorganism/gram (as per USP 23, p. 1684).       |
| 15 | 14. Test for Staphylococcus aureus     | Staphylococcus aureus is absent (as per USP 23, p. 1684).  |
|    | 15. Test for Pseudomonas aeruginosa    | Pseudomonas aeruginosa is absent (as per USP 23, p. 1684). |
| 20 | 16. Yeasts & Molds                     | NMT 200 CFU/gram (as per USP 23, p. 1686).                 |

This topical grade may then be sterilized.

Other forms may be suitable such as one form of hyaluronic acid and/or pharmaceutically acceptable salts thereof (for example, sodium salt) may be an amount also supplied by Hyal Pharmaceutical Corporation. One such amount is a 15 ml vial of Sodium hyaluronate 20mg/ml (300mg/vial - Lot 2F3). The sodium hyaluronate fraction is a 2% solution with a mean average molecular weight of about 225,000 (Protein Standard). The amount also contains water q.s. which is triple distilled and sterile in accordance with the U.S.P. for injection formulations. The vials of hyaluronic acid and/or salts thereof may be carried in a Type 1 borosilicate glass vial closed by a butyl stopper which does not react with contents of the vial.

The amount of hyaluronic acid and/or salts thereof (for example sodium salt) may comprise hyaluronic acid and/or salts thereof having the following characteristics:

a purified, substantially pyrogen-free fraction of hyaluronic acid obtained from a natural source having at least one characteristic selected from the group consisting of the following:

- 5 i) a molecular weight within the range of 150,000 - 225,000 (Protein Standard);
- ii) less than about 1.25% sulphated mucopolysaccharides on a total weight basis;
- iii) less than about 0.6% protein on a total weight basis;
- 10 iv) less than about 150 ppm iron on a total weight basis;
- v) less than about 15 ppm lead on a total weight basis;
- vi) less than 0.0025% glucosamine;
- vii) less than 0.025% glucuronic acid;
- viii) less than 0.025% N-acetylglucosamine;
- 15 ix) less than 0.0025% amino acids;
- x) a UV extinction coefficient at 257 nm of less than about 0.275;
- xi) a UV extinction coefficient at 280 nm of less than about 0.25; and,
- 20 xii) a pH within the range of 7.3 - 7.9. Preferably, the hyaluronic acid is mixed with water and the fraction of hyaluronic acid fraction has a mean average molecular weight within the range of 150,000 - 225,000 (Protein Standard).

25 Preferably this amount of hyaluronic acid comprises at least one characteristic selected from the group consisting of the following characteristics:

- i) less than about 1% sulphated mucopolysaccharides on a total weight basis;
- 30 ii) less than about 0.4% protein on a total weight basis;
- iii) less than about 100 ppm iron on a total weight basis;
- iv) less than about 10 ppm lead on a total weight basis;
- v) less than 0.00166% glucosamine;
- vi) less than 0.0166% glucuronic acid;
- 35 vii) less than 0.016% N-acetylglucosamine;
- viii) less than 0.00166% amino acids;

- ix) a UV extinction coefficient at 257 nm of less than about 0.23;
- x) a UV extinction coefficient at 280 nm of less than 0.19; and
- xi) a pH within the range of 7.5 - 7.7

Other forms of hyaluronic acid and/or its salts may be chosen from other suppliers, for example those described in prior art documents disclosing forms of hyaluronic acid having lower molecular weights between about 150,000 daltons and 750,000 daltons being prepared as for example, 1-2% solutions in sterile water for intravenous administration. In addition, sodium hyaluronate produced and supplied by LifeCore™ Biomedical, Inc. having the following specifications may be suitable (if sterile):

| 15 | Characteristics  | Specification                        |
|----|--|--------------------------------------|
|    | Appearance   | White to cream colored particles     |
|    | Odor   | No perceptible odor                  |
|    | Viscosity Average  | < 750,000 Daltons (Protein Standard) |
| 20 | Molecular Weight   |                                      |
|    | UV/Vis Scan, 190-820nm                                   | Matches reference scan               |
|    | OD, 260nm  | < 0.25 OD units                      |
|    | Hyaluronidase Sensitivity                                | Positive Response                    |
|    | IR Scan  | Matches reference                    |
| 25 | pH, 10mg/g solution                                      | 6.2 - 7.8                            |
|    | Water  | 8% maximum                           |
|    | Protein  | < 0.3 mcg/mg NaHy                    |
|    | Acetate  | < 10.0 mcg/mg NaHy                   |
|    | Heavy Metals, maximum ppm                                |                                      |
| 30 | As    Cd    Cr    Co    Cu    Fe    Pb    Hg    Ni       |                                      |
|    | 2.0   5.0   5.0   10.0   10.0   25.0   10.0   10.0   5.0 |                                      |
|    | Microbial Bioburden                                      | None observed                        |
|    | Endotoxin  | < 0.07EU/mg NaHy                     |
| 35 | Biological Safety Testing                                | Passes Rabbit Ocular Toxicity Test   |

The following references teach hyaluronic acid, sources thereof and processes of the manufacture and recovery thereof.

Canadian Letters Patent 1,205,031 (which refers to United States Patent 4,141,973 as prior art) refers to hyaluronic acid fractions  
5 having average molecular weights of from 50,000 to 100,000; 250,000 to 350,000; and 500,000 to 730,000 (Protein Standard) and discusses processes of their manufacture.

Where high molecular weight hyaluronic acid (or salts or other forms thereof) is used, it must, prior to use, be diluted to permit  
10 administration and ensure no intramuscular coagulation. (Preferably they should be autoclaved to reduce their molecular weight.) Recently, it has been found that large molecular weight hyaluronic acid having a molecular weight exceeding about 1,000,000 daltons self-aggregates and thus, does not interact very well with HA receptors. Thus, the larger  
15 molecular weight hyaluronic acid should be avoided (such as Healon™).

For making the oral dosage forms more pleasant to take taste enhancers or flavours may be added to make the taking more pleasant provided the form of the hyaluronan is not adversely affected (degraded, disassociated or bound up with other materials so as not to be suitable  
20 herein). Additionally the dosages may be mixed with a drink liquid to be more enjoyable to take provided the form of hyaluronan is not adversely affected. The dosages may also be taken straight (without their addition to any drink) as there is really no unpleasant flavour.

The invention relates to oral dosages containing forms of  
25 hyaluronan and the oral administration thereof to treat or prevent a disease or condition. Thus, the invention can be used for restenosis prevention and other treatments in the same manner that hyaluronan is used. Thus, the invention can be used for the treatments and preventative therapies discussed in the following published and unpublished documents identified below and for the purposes in  
30 Canadian Patent Application Serial No. 2,164,260, filed in the Canadian Patent Office on the 1st day of December, 1995 entitled "*Targeting of Dosages of Medicines and Therapeutic Agents*", and Canadian Patent Application Serial Number 2,173,037, filed on the 29th day of March, 1996  
35 entitled "*Targeting of Dosages of Medicines and Therapeutic Agents and other Glycosaminoglycans (GAGS)*", each of which documents is

incorporated herein by reference: (with respect to the teachings of each of the documents, the dosages of hyaluronan may be substituted by the oral dosages referred to herein and be used in like manner)

|    | <u>PCT Application</u> | <u>International Publication</u> | <u>U.S. Application</u> |
|----|------------------------|----------------------------------|-------------------------|
| 5  | PCT/CA90/00306         | WO 91/04058                      | Serial No. 07/675,908   |
|    | PCT/CA93/00061         | WO 93/16732                      | Serial No. 08/290,840   |
|    | PCT/CA93/00062         | WO 93/16733                      | Serial No. 08/290,848   |
|    | PCT/CA93/00388         | WO 94/07505                      | Serial No. 07/952,095   |
|    | PCT/CA94/00207         | WO 94/23725                      | Serial No. 08/448,504   |
| 10 | PCT/CA95/00243         | WO 95/29683                      | Serial No. 08/464,769   |
|    | PCT/CA94/00188         | WO 95/26193                      | Serial No. 08/448,503   |
|    | PCT/CA95/00259         | WO 95/30423                      | Serial No. 08/464,768   |
|    | PCT/CA95/00467         |                                  | Serial No. 08/295,390   |
|    | PCT/CA95/00477         |                                  | Serial No. 08/468,328   |

15 As an example, I have extracted from Application PCT/CA90/00306 (International Publication No. WO 91/04058) the following to illustrate just some of the uses:

(i) at page 17, line 3 to page 18, line 16:

20 "Applicants have now discovered that combinations and formulations (for example an injectable formulation) can be provided for administration to a mammal for the treatment of a disease or condition, which combinations or formulations employ or incorporate as the case may be a therapeutically effective non-toxic amount of a medicinal and/or therapeutic agent to treat the

25 disease or condition (for example a free radical scavenger (for example ascorbic acid (Vitamin C)), Vitamin C (for the treatment of mononucleosis), an anti-cancer agent, chemotherapeutic agent, anti-viral agents for example a nonionic surfactant, e.g. nonoxynol-9 [nonylphenoxy polyethoxy ethanol] found in Delfen™

30 contraceptive cream, and anionic surfactants (e.g. cetyl pyridinium chloride) and cationic surfactants (e.g. benzalkonium chloride), non-steroidal anti-inflammatory drugs (NSAID) for example indomethacin, naproxen and (+/-) tromethamine salt of ketorolac (sold under the trademark Toradol™) and steroidal anti-inflammatory drugs, anti-fungal agent, detoxifying agents (for

35 example for administration rectally in an enema), analgesic,



5 bronchodilator, anti-bacterial agent, antibiotics, drugs for the treatment of vascular ischemia (for example diabetes and Berger's disease), anti-body monoclonal agent, minoxidil for topical application for hair growth, diuretics (for example furosemide (sold under the trademark Lasix<sup>TM</sup>)), immunosuppressants (for example cyclosporins), lymphokynes (such as interleukin - 2 and the like),  
10 alpha-and- $\beta$ -interferon and the like) administered with, or carried in, an amount of hyaluronic acid and/or salts thereof (for example the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub units of hyaluronic acid (preferably hyaluronic acid and salts thereof) sufficient to facilitate the agent's penetration through the tissue (including scar tissue), at the site to be treated through the cell membranes into the individual cells to be treated. When such combinations and  
15 formulations are administered to patients suffering from the disease or condition, the disease or condition is unexpectedly improved.

The formulation can be administered among other methods, intravenously, intra arterially, intraperitoneally, intrapleurally, transdermally, on the skin (topically), rectally, orally or by direct  
20 injection (for example into a tumor, into an abscess or similar disease focus) or put on a patch to be secured to the skin of the patient. The hyaluronic acid and/or salts thereof and the agent can be administered separately but are administered in sufficient amounts and in an immediate time sequence or interval (preferably concurrently and more preferably simultaneously), preferably at the identical site (e.g. one given intravenously and the other "piggy backed"), to treat the disease or condition."

25 Thus this invention also provides oral dosages comprising effective amounts of the forms of hyaluronan herein described with effective amounts of medicines and/or therapeutic agents and the oral administration of these oral dosages for the treatment and prevention of disease and/or conditions of the human body.

30 The invention will now be illustrated with reference to the following Figures and Detailed Description of Embodiments:  
35

**FIGURE 1** depicts Aggrecan Assay used for the Determination of standardization of Hyaluronic Acid in plasma.

**FIGURE 2** illustrates a summary of Time Course of Rat Serum HA levels after oral administration of Hyaluronic Acid at 30 mg/kg (Mean Average Molecular Weight Distribution of 400,000 daltons (Protein Standard) (2% by weight in solution 30,000 to greater than 70,000 daltons (30- > 70kDa) (using protein standards)).

**FIGURE 3** illustrates Time Course of Rat Serum Hyaluronan (HA) levels after oral administration of sodium hyaluronate at 30mg/kg, mean average molecular weight distribution of 400,000 daltons (Protein Standard) (2% by weight in solution 30,000 to greater than 70,000 daltons (30- > 70kDa)).

**FIGURE 4** illustrates Gel Filtration Chromatography of rat serum after oral administration of Hyaluronic Acid administered to each rat at 30 mg of hyaluronan per kilogram of body weight of each rat.

**FIGURE 5** illustrates Time Course of Subcutaneous and Intravenous administration of HA (same mean average molecular weight distribution) for comparison with oral HA.

**FIGURE 6** presents a series of photos of stenosis following Hyaluronan (HA) administration of rats wherein:

**FIGURE 6A** is a photograph of the cross-section of a rat artery showing the state of the rat artery after balloon angioplasty and after being left to heal on its own.

**FIGURE 6B** is a photograph of the cross-section of a rat artery showing the state of the rat artery after balloon angioplasty, given normal saline orally and left to heal.

**FIGURE 6C** is a photograph of the cross-section of a rat artery showing the state of the rat artery after balloon angioplasty and given orally 1 mg/kg of the body weight of the rat of sodium hyaluronate, 2% by weight solution in sterile water) and left to heal.

**FIGURE 6D** is a photograph of the cross-section of a rat artery showing the state of the rat artery after balloon angioplasty and given orally 3 mg/kg of the body weight of the rat of sodium hyaluronate, 2% by weight solution in sterile water) and left to heal.

FIGURE 6E is a photograph of the cross-section of a rat artery showing the state of the rat artery after balloon angioplasty and given orally 10 mg/kg of the body weight of the rat of sodium hyaluronate, 2% by weight solution in sterile water) and left to heal.

FIGURE 6F is a photograph of the cross-section of a rat artery showing the state of the rat artery after balloon angioplasty and given orally 30 mg/kg of the body weight of the rat of sodium hyaluronate (M.W. 400,000 daltons (Protein Standard), 2% by weight solution in sterile water) and left to heal.

FIGURE 6G is a photograph of the cross-section of a rat artery showing the state of the rat artery after balloon angioplasty and given orally 100 mg/kg of the body weight of the rat of sodium hyaluronate (M.W. 400,000 daltons (Protein Standard), 2% by weight solution in sterile water) and left to heal.

(After healing, each of the rats was sacrificed and the carotid arteries harvested and examined)

FIGURE 7 illustrates the effects of oral hyaluronan administration of various concentration of hyaluronic acid on neointimal formation in rats after balloon angioplasty.

FIGURE 8 is a chart depicting MPO content (oral) (MPO - Myeloperoxidase assay) which detects neutrophils

FIGURES 9A, 9B and 9C illustrate in tabular form the concentration of hyaluronan in rat blood serum after oral administration of various amounts of hyaluronan (m.w. less than 750,000 daltons determined by Protein Standard).

FIGURE 10 illustrates serum levels of hyaluronic acid ( $\mu\text{g/ml}$ ) following the administration of hyaluronic acid in humans (300 mg/kg of body weight orally (average molecular weight administered less than 750,000 daltons - Protein Standard).

FIGURES 11A, 11B and 11C illustrate molecular weights of hyaluronan determined by Dextran Standard, in three humans orally administered hyaluronan (m.w. less than 500,000 daltons, Dextran Standard).

FIGURES 12A and 12B each depict standard curve for the same originally administered HA as detected by protein standards [Fig. 12A] and dextran standards [Fig. 12B]

**DETAILED DESCRIPTION OF EMBODIMENTS**

**FIGURE 2** Hyaluronan levels for blood after oral administration in several animals.

**FIGURE 3** Hyaluronan administered orally to rats appears as a burst of HA in blood one hour after administration, a decrease for five hours followed by a steady increase over the next eighteen hours in a time dependent manner. (Background levels of HA are 1000-1500 ng/ml). Note molecular weight of HA recalls a higher range than in IV administered HA (see Figure 3).

**FIGURE 5** Molecular weight and amounts of HA in blood after subcutaneous administration. Note that the amounts of HA in blood after subcutaneous and oral administration are similar. Also note that in both cases the molecular weight of released HA released from a subcutaneous depot reaches a higher range than that of administered I.V.

**FIGURE 6** consists of a series of photographs of the cross-sections through carotid arteries of rats showing the effects of different amounts of orally administered Hyaluronan in stenosis of the rat carotid arteries:

All vessels were injured with a Fogarty balloon as described in the prior art (Forns et. al., 1994) Cross-sections of arteries of rats treated with HA, saline or left untreated are as shown:

**FIGURE 6A)** no treatment

**FIGURE 6B)** saline treated

**FIGURE 6C)** 1 mg/kg hyaluronan

**FIGURE 6D)** 3 mg/kg hyaluronan

**FIGURE 6E)** 10 mg/kg hyaluronan

**FIGURE 6F)** 30 mg/kg hyaluronan

Optimal effects on smooth muscle cell proliferation were noted between about 3-10 mg/kg Hyaluronan oral administration. (The neointima to intima ratios were smaller - see Figure 7.)

QUANTIFICATION OF WHAT IS SHOWN IN THE PHOTOGRAPHS IN  
FIGURES 6A-6G

**TABLE 1:**

5 Table 1. Effect of orally administered hyaluronan (HA) in stenosis after balloon (angeoplasty) injury of the rat carotid artery. (FIGURES 6A-6G)

| DOSE                     | N/I RATIO $\pm$ S.E.M. | (NEOINTIMA/INTIMA RATIO<br>WHERE N IS NEOINTIMA AND<br>I IS INTIMA) |
|--------------------------|------------------------|---|
| (FIG. 6A) No treatment   | 2.5 $\pm$ 0.9          |   |
| (FIG. 6B) Saline         | 2.8 $\pm$ 0.7          |   |
| (FIG. 6C) 1 mg/kg (HA)   | 2.6 $\pm$ 0.8          |   |
| (FIG. 6D) 3 mg/kg (HA)   | 1.7 $\pm$ 0.4          |   |
| (FIG. 6E) 10 mg/kg (HA)  | 0.4 $\pm$ 0.03         |   |
| (FIG. 6F) 30 mg/kg (HA)  | 0.99 $\pm$ 0.06        |   |
| (FIG. 6G) 100 mg/kg (HA) | 1.1 $\pm$ 0.08         |   |

10 These values represent the mean of, and standard error of the mean (S.E.M.) of, four animals. These experiments were repeated twice with similar results.

15 What is shown in each photo represents a cross-section of the rat artery as shown in Figure 13.

20

25

## METHODOLOGY

- 5     Elisa-Like Assay for Hyaluronic Acid in Column Fractions from Serum  
      Obtained after the Oral Administration of Sodium Hyaluronate at 30  
      mg/kg (400,000) Daltons Mean Average Molecular Weight Distribution  
      (Protein Standard), 2% by weight in sterile water)

10

### **A.) Chromatography**

- using 2 mL fraction volumes.

### **B.) Elisa-Like Assay for Hyaluronic Acid**

- 15    -Prior to assay the column fractions were prepared in the following manner:

-1900  $\mu$ L of each 2 mL fraction was frozen at - 80°C and then taken to dryness on a speed vac concentrator at room temperature.

20

-fractions were reconstituted with 125  $\mu$ L of ddH<sub>2</sub>O and then assayed.

### **C.) Discussion of Data in Figure 3**

- 25    The data has been summarized in Figure 3. The results show that the oral administration of sodium hyaluronate, (M.W-750,000 daltons (determined by Protein Standard), 2% by weight in sterile water), at a

single dose of 30 mg/kg, results in an increase in serum hyaluronic acid on the order of that seen for the subcutaneous administration of this compound at 30-100 mg/kg. Figure 3 indicates that serum hyaluronic acid levels are increased within the first hour after oral administration of sodium hyaluronate, followed by a sharp decrease to background levels in normal serum at 3 and 6 hours post-feeding. Serum hyaluronic acid levels are again found to increase at 9 hours post-feeding of HA and this increase is sustained over the time period extending up to 24 hours post-feeding of HA. The sharp drop in serum hyaluronic acid levels seen at 3 and 6 hours post-feeding appears to be a real event since it was reproduced in serum analyzed from two different animals for each time point. The overall trend appears to be satisfactory. It is indicative of an initial absorption of sodium hyaluronate in the stomach (1 hour post-feeding of HA) followed by a rapid clearance of this initial "pulse" from the blood. The second "pulse" of increased serum hyaluronic acid (9-12 hours post-feeding of HA) appears then to represent a second phase of absorption, as the administered sodium hyaluronate moves into the small and large intestine. The majority of serum hyaluronic acid at 1 hour and 9 hours post-feeding of HA (Figure 3 (A), (D)) elutes in the region of V, indicating a molecular weight >71 kDa (Kilodaltons (high molecular weight species). Between 12-24 hours post-feeding (figure 3 (E), (G)), there appears to be an emergence of smaller molecular weight hyaluronic acid species in the molecular weight range between about 30 and about >80 kDa, and more particularly between 71-37.7 kDa (Kilo-daltons (peaks 1,2 and 3 in Figure 1(G), representing 55.5, 47 and 38 kDa, respectively (Protein Standard). Two assays were used to measure HA in serum: (i) carbazole, and (ii) aggrecan assay.

#### **F: Carbazole Assay for the Determination of Glucuronic Acid**

-See enclosed Figure 6

##### **Materials**

##### **A. Chemicals**

-Carbazole (99%): Aldrich Chemical Co., cat. no.. C308-1.

-Borax (Sodium Tetraborate.10 H<sub>2</sub>O): Sigma Chemical Co., prod. no. B-9876).

-Sodium Hyaluronate: Hyal Pharmaceutical Corporation (Applicant)

-H<sub>2</sub>SO<sub>4</sub> (AR) analytical reagent: Mallinckrodt Specialty Chemicals Co.

**B. Apparatus**

-Hot water bath.

-Vortex mixer.

5 -12 x 75 mm disposable glass culture tubes: Fischer Chem. Co., cat. no. 14-958-C.

-Visible spectrophotometer or Elisa microplate reader.

-96 well, Sarstedt polystyrene microtest plates (For microplate assay): Sarstedt Canada, order no. 82.1581.100.

10 **General Procedure**

-Prepare a series of hyaluronic acid standards and solutions of 0.025 M sodium tetraborate.10H<sub>2</sub>O in concentrated H<sub>2</sub>SO<sub>4</sub> and 0.125% carbazole in absolute ethanol. For this assay, a linear response has been achieved with hyaluronic acid standards up to 200 µg./mL, (the range of linearity is  
15 expected to be extendible to even higher standard concentrations).

-Place 3 mL of 0.025 M sodium tetraborate solution in glass tubes and cool thoroughly on ice prior to addition of samples and standards.

-Carefully layer (so as to avoid mixing) 0.5 mL of sample or standard over the sodium tetraborate solution in the reaction tubes and place tubes back  
20 on ice until all tubes have been prepared.

-Mix the contents of each tube thoroughly with a vortex mixer and return the tube to the ice, while mixing the others, to prevent excessive heating of sample.

-Place reaction tubes in a 90°C water bath for 10 minutes and then transfer  
25 to a tub of cool water for 5-10 minutes.

-Add 100 µ.L of 0.125% carbazole solution to each tube and mix thoroughly with a vortex mixer.

-Re-heat the reaction tubes in the 90°C water bath for an additional 15 minutes. Transfer to a tub of cool water for 5-10 minutes.

30 -Measure absorbance of samples and standards at 530 nm.

**Procedure using Microtest Plates (ELISA'S)**

-For the carbazole reaction, follow *general procedure*- as outlined; however, the following volume reductions should be introduced into the procedure: 0.5 mL sodium tetraborate solution per tube, 83.3 µ.L. of  
35 sample or standard and 16.6 µ.L. of 0.125% carbazole.



-After completion of the reaction, transfer 200  $\mu$ L of each sample and standard to individual wells of a 96 well microtest plate. Immediately measure the sample absorbance at 530 nm (550 nm, given the available filters with some instruments) using a microplate reader. Biotinylated  
5 Aggregcan, an HA binding protein, can be used to detect low levels of HA in serum by in ELISA assay that has been published and is known to persons skilled in the art. This assay is more sensitive than the carbazole assay and was used for conformation.

With respect to neutrophil accumulation, reference is to be  
10 had to Figure 8 - MPO Content (oral) where MPO is Myeloperoxidase and MPO has been assayed by the methods known to persons skilled in the art. This assay for detecting myeloperoxidase (which is an enzyme) is a good test and thus a good measure for detecting neutrophils.

Thus having regard to Figure 8, it is clear that the presence of  
15 hyaluronic acid (HA) at the site of restenosis, reduces the number of neutrophils. While there appears to be little difference between the bars labelled 1-4, nevertheless there is a substantial difference between those and bars 5-7. It is also clear that the response is phasic (as opposed to a linear dependence - the more hyaluronan, the better the results). In fact  
20 the optimal oral administration results appear between about 3 to about 10 mg/kg administered orally.

With reference to Figure 4, (as with Figure 3), the serum hyaluronan levels after oral administration of hyaluronan to rats increases after about 1.25 hours after administration in rats (m.w. daltons  
25 determined by Protein standard) followed by a sharp decrease to background levels in normal serum at 3 and 6 hours post-feeding of HA. Serum hyaluronan levels are again found to increase at 9 hours post feeding of HA, and this increase is sustained over an extended period. Note the molecular weights of the hyaluronan in the serum closely  
30 follow molecular weights of the serum hyaluronan identified in Figure 3.

With reference to Figure 4, the hyaluronan given orally is initially absorbed in the stomach providing the first pulse, and then as a result of absorption in the small and large intestine, gives a second pulse of hyaluronan in the serum. Hyaluronic acid has previously been shown  
35 to be absorbed across the large intestine wall when experimentally perfused in this organ.

Thus it is possible by suitable oral administration of dosages of hyaluronan to provide a sustained release of HA into the body - such as by for example, administration at time 0, followed by a sustaining dosage at 3 hours, then repeated after 24 hours, 48 hours, etc. (see Figure 3) will provide the sustaining dosage.

Figure 7 illustrates the effects of oral administration of HA on Neointimal formation in rats after balloon angioplasty. Six groups of tests were conducted, each test in respect of 3 rats. Thus, the six test results shown in Figure 8 resulted from the use of 18 rats. It is clear the neointimal to total wall ratio (see illustration at page 18) is greater for administration of saline, followed by the administration of HA in amounts per kilogram of body weight of 1 mg, then 100 mg, 10 mg and 3 mg. This is consistent with the findings illustrated in Figures 6 and 8 and the discussion herein.

Figures 11A, 11B and 11C illustrate the release of amounts of hyaluronic acid into the blood stream of individuals (human) who have taken hyaluronan orally and the molecular weights of the serum hyaluronan released by the bodily processes. The molecular weights of the hyaluronan released into the human blood serum appear to include amounts at peaks between 400,000 daltons and 600,000 daltons such as less than 500,000 daltons, between about 200,000 and about 300,000 such as greater than 200,000 daltons, and between about 30,000 daltons and about 80,000 daltons (determined using the Dextran Standard).

Figures 9A, 9B and 9C provide Tables illustrating the amounts of serum hyaluronan in rats at various times after administration of various oral dosages of hyaluronan (3, 10 and 30 mg hyaluronan per kilogram of rat body weight). "M" is the amount ( $\mu\text{g}/\text{ml}$ , also  $\mu\text{g}/\text{L}$ ); "SD" is the standard deviation and "SE" is the standard error.

Figure 10 illustrates the mean serum hyaluronan concentration after giving individual humans oral dosages containing 30.0 mg/kg of hyaluronan (molecular weight less than 750,000 daltons determined by the Protein Standard). The increased serum presence of hyaluronan exhibited increased levels of serum hyaluronan between about hours 4 - 12.

Thus, a suitable therapeutic regimen for sustained presence and maintenance of therapeutic levels of HA can be provided by orally

administering suitable oral dosage amounts of HA (eg. 3-10 mg/kg of body weight of a human in a suitable form (eg. 2% solution in saline or sterile water) for oral administration to provide a therapeutic serum level of HA in the blood such as to inhibit restenosis.

5               Where medicines or therapeutic agents can be given orally, therapeutically effective amounts of the medicine and therapeutic agents can be administered with the HA. The HA when going into the serum, takes the medicine/therapeutic agent with it into the serum and the medicines/therapeutic agents are transported to the sites in need of  
10 treatments (sites for example of trauma, disease focus, pathological tissue, underperfusion, and inflammation expressing excess Hyaluronan (HA) receptors). Thus, suitable therapeutic regimens of treatment can be prepared to provide sustained therapeutic levels of hyaluronan in the body by oral administration (with or without a medicine or therapeutic  
15 agent).

              These therapeutic sustained levels of hyaluronan can easily be determined from the kinetics of the delivery of hyaluronan into the serum by oral administration of hyaluronan (with or without a therapeutic agent/medicine).

20               It also appears that where high molecular weight hyaluronan is given orally to a patient, the body reduces the molecular weight of the hyaluronan released into the blood serum to have a lesser molecular weight (for example about 30,000 daltons - > 80,000 daltons [determined by Protein Standard]). Therefore, giving to a human Hyaluronan, having a  
25 mean average molecular weight in the order of between about 30,000 to about 80,000 daltons (Protein Standard), between about 200,000 daltons and about 300,000 daltons (determined by the Dextran Standard), and between about 400,000 daltons and 600,000 daltons (determined by the Dextran Standard), saves the human body from having to reduce the molecular  
30 weight of the orally administered hyaluronan. (See for example Figures 1, 5, 4 and 11A-C.) Figures 12A and 12B each depict standard curves for the same originally administered hyaluronan (HA) whose molecular weight was determined using the weight by Protein Standard (Figure 12A) and the Dextran Standard (Figure 12B). The conversion factor from the  
35 Molecular Weight Determination by Dextran Standard to the Molecular Weight Determination by the Protein Standard has been calculated from

the curves as in the order of about 3.3. To convert the Molecular Weight Determination (Dextran Standard) to Molecular Weight Determination (Protein Standard), one must divide the Molecular Weight of the Dextran Standard by 3.3. To convert the Molecular Weight of the Protein Standard to the Molecular Weight of the Dextran Standard one must multiply the Molecular Weight Protein Standard.

As many changes can be made to the embodiments of the invention without departing from the scope of the invention, it is intended that all material herein be interpreted as illustrative of the invention and not in a limiting sense.

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE AS FOLLOWS:

1. An orally administrable dosage of a form of hyaluron comprising suitable excipients for oral administration and an effective amount of at least one of the following:

- (i) between about 3 mg of the form of hyaluronan /kg to about 100 mg of the form of hyaluronan /kg of the body weight of the human taking the orally administrable dosage and
- (ii) the form of hyaluronan in the orally administrable dosage having a mean average molecular weight distribution in the range selected from the following group of ranges of molecular weights:
  - (a) a range between about 30,000 and greater than 80,000 daltons (determined by either the Protein Standard),
  - (b) a range between about 30,000 daltons and about 2,000,000 daltons (determined by the Dextran Standard)

wherein the form of hyaluronan is selected from hyaluronan and pharmaceutically acceptable salts thereof.

2. The orally administrable dosage of claim 1 in accordance with subparagraph (i).

3. The orally administrable dosage of claim 1 in accordance with subparagraph (ii).

4. The orally administrable dosage of claim 1 in accordance with subparagraph (ii) (a).

5. The orally administrable dosage of claim 1 in accordance with subparagraph (ii) (b).

6. The orally administrable dosage of claim 1 in accordance with both subparagraphs (i) and (ii).

7. The orally administrable dosage of claim 1, 2, 3, 4, 5 or 6 wherein the form of hyaluronan is present between about 3 mg/kg and about 10mg/kg of the human of the form of hyaluronan.
8. The orally administrable dosage of claim 1, 2, 3, 4, 5 or 6 wherein the form of hyaluronan is present between about 3 mg/kg and about 30mg/kg of the human of the form of hyaluronan.
9. The orally administrable dosage of claim 2 wherein the mean average molecular weight distribution of the form of hyaluronan is less than 750,000 daltons (Protein Standard).
10. The orally administrable dosage of claim 2 wherein the mean average molecular weight distribution is about 400,000 daltons (Protein Standard).
11. An orally administrable dosage of a form of hyaluronan in a suitable excipient wherein the form of hyaluronan is selected from hyaluronan and pharmaceutically acceptable salts thereof and wherein the oral dosage provides a mean average molecular weight distribution in the blood system between about 30,000 and greater than 70,000 daltons (Protein Standard).
12. An orally administrable dosage of a form of hyaluronan in a suitable excipient wherein the form of hyaluronan is selected from hyaluronan and pharmaceutically acceptable salts thereof and wherein the oral dosage provides a mean average molecular weight distribution in the blood system between about 30,000 and about 2,000,000 daltons (Dextran Standard).
13. The orally administrable dosage of claim 11 or 12 wherein the form of hyaluronan is between about 3 mg of the form of hyaluronan/kg to about 100 mg of the form of hyaluronan/kg of the body weight of the human taking the orally administrable dosage.

14. The orally administrable dosage of claim 11 or 12 wherein the form of hyaluronan is present between about 3 mg/kg and about 30mg/kg of the human of the form of hyaluronan.

15. The orally administrable dosage of claim 11 or 12 wherein the form of hyaluronan is present between about 3 mg/kg and about 10mg/kg of the human of the form of hyaluronan.

16. The orally administrable dosage of the form of hyaluronan according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 further comprising a therapeutically effective amount of medicine and/or therapeutic agent.

17. A method of treating or preventing a condition or disease which may employ the use of a form of hyaluronan in the treatment or preventative measure, the method comprising orally administering an effective amount of an orally administrable dosage of a form of hyaluron comprising suitable excipients for oral administration and an effective amount of at least one of the following:

(i) between about 3 mg of the form of hyaluronan /kg to about 100 mg of the form of hyaluronan /kg of the body weight of the human taking the orally administrable dosage

and

(ii) the form of hyaluronan in the orally administrable dosage having a mean average molecular weight distribution in the range selected from the following group of ranges of molecular weights:

(a) a range between about 30,000 and greater than 70,000 daltons (determined by either the Protein Standard or the Dextran Standard),

(b) a range between about 30,000 daltons and about 2,000,000 daltons (determined by the Dextran Standard)

wherein the form of hyaluronan is selected from hyaluronan and pharmaceutically acceptable salts thereof, the said administration continuing over such period of time as required.

18. The method of claim 17 wherein the orally administrable dosage is in accordance with subparagraph (i).
19. The method of claim 17 wherein the orally administrable dosage is in accordance with subparagraph (ii).
20. The method of claim 17 wherein the orally administrable dosage is in accordance with subparagraph (ii) (a).
21. The method of claim 17 wherein the orally administrable dosage is in accordance with subparagraph (ii) (b).
22. The method of claim 17 wherein the orally administrable dosage is in accordance with both subparagraphs (i) and (ii).
23. The method of claim 17, 18, 19, 20, 21 or 22 wherein the form of hyaluronan is present between about 3 mg/kg and about 30mg/kg of the human of the form of hyaluronan.
24. The method of claim 17, 18, 19, 20, 21 or 22 wherein the form of hyaluronan is present between about 3 mg/kg and about 10mg/kg of the human of the form of hyaluronan.
25. The method of claim 18 wherein the mean average molecular weight distribution of the form of hyaluronan is less than 750,000 daltons (Protein Standard).
26. The method of claim 18 wherein the mean average molecular weight distribution is about 400,000 daltons.
27. A method of treating or preventing a condition or disease which may employ the use of a form of hyaluronan in the treatment or preventative measure, the method comprising administering an effective amount of an orally administrable dosage of a form of hyaluronan in a suitable excipient wherein the form of hyaluronan is selected from hyaluronan and pharmaceutically acceptable salts thereof and wherein the oral dosage provides a mean average molecular weight distribution in the



blood system between about 30,000 and greater than 70,000 daltons (Protein Standard), the said administration continuing over such period of time as required.

28. A method of treating or preventing a condition or disease which may employ the use of a form of hyaluronan in the treatment or preventative measure, the method comprising administering an effective amount of an orally administrable dosage of a form of hyaluronan in a suitable excipient wherein the form of hyaluronan is selected from hyaluronan and pharmaceutically acceptable salts thereof and wherein the oral dosage provides a mean average molecular weight distribution in the blood system between about 30,000 and about 2,000,000 daltons (Dextran Standard), the said administration continuing over such period of time as required.

29. The method of claim 27 or 28 wherein the form of hyaluronan is between about 3 mg of the form of hyaluronan /kg to about 100 mg of the form of hyaluronan /kg of the body weight of the human taking the orally administrable dosage.

30. The method of claim 27 or 28 wherein the form of hyaluronan is present between about 3 mg/kg and about 30mg/kg of the human of the form of hyaluronan.

31. The method of claim 27 or 28 wherein the form of hyaluronan is present between about 3 mg/kg and about 10mg/kg of the human of the form of hyaluronan.

32. The method of claim 17, 18 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 wherein the orally administrable dosage further comprises a therapeutically effective amount of a medicine and/or therapeutic agent.

33. The method of claim 17, 27 or 28 wherein the treatment or preventing of disease or condition is the prevention of restenosis.

34. The method of claim 33 wherein the period of time of administration is over a 3-5 day period.

1/19

Aggrecan Assay for the Determination of Hyaluronic Acid  
Standard Curve





FIG. 1

2/19



Time Course of Rat Serum Hyaluronic Acid Levels After  
Oral Administration of Hyaluronic Acid at 30 mg/kg  
(Mean Average Molecular Distribution 400,000 Daltons)  
(2% by weight in solution)



Data for each time point represents the sum of hyaluronic acid levels (ng/mL) in individual fractions collected during gel filtration chromatography of 1 mL rat serum. Error bars represent the mean  $\pm$  SE for duplicate assays of serum from a single animal (  ) or the assay of serum from two separate animals (  ).

FIG. 2

3/19

Time Course of Rat Serum Hyaluronic Acid Levels After Oral Administration  
of Sodium Hyaluronate at 30 mg/kg Molecular Weight 400,000 Daltons  
(Protein Standard) (2% by weight solution in sterile water)




FIG. 3

4/19

Gel Filtration Chromatography of Rat Serum After  
Oral Administration of Hyaluronic Acid at 30 mg/kg

Difference Chromatograms  
(corrected for background of normal serum)




FIG. 4

5/19




FIG. 5

6/19




FIG. 6A to 6D

7/19




FIG. 6E to 6G



8/19

Effect of Oral HA on Neointimal Formation  
in Rats After Ballon Angioplasty





FIG. 7

9/19



(HA = Form of Hyaluronan)

**FIG. 8**

10/19

|                 | <u>Time in<br/>Hours</u> | <u>Amounts</u> | <u>Amount in Rat Blood Stream<br/>ng/ml (µg/L)</u> |
|-----------------|--------------------------|----------------|--|
| ORAL<br>30mg/kg | 4                        | 933            | 1220.00 M  |
|                 |                          | 549            | 695.31 SD  |
|                 |                          | 2178           | 401.44 SE  |
|                 | 8                        | 502            | 1156.67 M  |
|                 |                          | 1964           | 606.54 SD  |
|                 |                          | 1004           | 350.19 SE  |
|                 | 12                       | 1668           | 1837.67 M  |
|                 |                          | 1973           | 126.86 SD  |
|                 |                          | 1872           | 73.24 SE   |
|                 | 24                       | 2280           | 1985.00 M  |
|                 |                          | 2008           | 250.78 SD  |
|                 |                          | 1667           | 144.79 SE  |
|                 | 48                       | 6336           | 3624.67 M  |
|                 |                          | 3557           | 2186.69 SD   |
|                 |                          | 981            | 1262.49 SE   |
|                 | 72                       | 4187           | 2743.00 M  |
|                 |                          | 1057           | 1289.22 SD   |
|                 |                          | 2985           | 744.33 SE  |

FIG. 9A

11/19

|                 | <u>Time in<br/>Hours</u> | <u>Amounts</u> | <u>Amount in Rat Blood Stream</u><br>ng/ml ( $\mu$ g/L) |
|-----------------|--------------------------|----------------|---|
| ORAL<br>10mg/kg | 3                        | 267.7          | 655.80 M  |
|                 |                          | 256.8          | 556.58 SD   |
|                 |                          | 1442.9         | 321.34 SE   |
|                 | 7                        | 1284.7         | 703.60 M  |
|                 |                          | 122.5          | 581.10 SD   |
|                 |                          |                | 410.90 SE   |
|                 | 12                       | 458            | 359.50 M  |
|                 |                          | 261            | 98.50 SD  |
|                 |                          |                | 69.65 SE  |
|                 | 24                       | 1018.1         | 1698.05 M   |
|                 |                          | 2378           | 679.95 SD   |
|                 |                          |                | 480.80 SE   |
|                 | 48                       | 2981.7         | 3249.00 M   |
|                 |                          | 3516.3         | 267.30 SD   |
|                 |                          |                | 189.01 SE   |
|                 | 72                       | 2491.9         | 2691.95 M   |
|                 |                          | 2892           | 200.05 SD   |
|                 |                          |                | 141.46 SE   |

FIG. 9B

12/19

|                | <u>Time in<br/>Hours</u> | <u>Amounts</u> | <u>Amount in Rat Blood Stream<br/>ng/ml (µg/L)</u> |
|----------------|--------------------------|----------------|--|
| ORAL<br>3mg/kg | 4                        | 225            | 551.67 M   |
|                |                          | 524            | 278.70 SD  |
|                |                          | 906            | 160.91 SE  |
|                | 8                        | 3822           | 2529.67 M  |
|                |                          | 2592           | 1081.53 SD   |
|                |                          | 1175           | 624.42 SE  |
|                | 12                       | 2029           | 1363.33 M  |
|                |                          | 695            | 544.61 SD  |
|                |                          | 1366           | 314.43 SE  |
|                | 24                       | 1139           | 1547.00 M  |
|                |                          | 933            | 727.54 SD  |
|                |                          | 2569           | 420.05 SE  |
|                | 48                       | 735            | 625.33 M   |
|                |                          | 905            | 283.91 SD  |
|                |                          | 236            | 163.92 SE  |
|                | 72                       | 501            | 3701.00 M  |
|                |                          | 6844           | 2589.83 SD   |
|                |                          | 3758           | 1495.24 SE   |

FIG. 9C

13/19

Serum Hyaluronic Acid Concentration ( $\mu\text{g/L}$ )  
Following Administration of Hyaluronic Acid  
(30.0 mg/kg, per os) Orally




FIG. 10

14/19

SJT3 – Molecular Weight Calibration  
Sephacryl 500–HR 1.6x61.5 cm Column #1




FIG. 11A

15/19

SJT2 – Molecular Weight Calibration  
Sephacryl 500–HR 1.6x61.5 cm Column #1




FIG. 11B



16/19

SJT1 – Molecular Weight Calibration  
Sephacryl 500–HR 1.6x61.5 cm Column #1





FIG. 11C

17/19

## Protein Standards




Reflects use of same originally administered Hyaluronan (HA) as that used for determining molecular weight by Dextran Standard in Figure 12B.

FIG. 12A

18/19

## Dextran Standards

Hyaluronic Acid (mol. wt. 300-500kDa)  
on Sephacryl 500-HR 1.6x61.5 cm Column



- hyaluronic acid (Hyal Corp.) 10 mg/mL
- diluted 1:100 (.05M phosphate buffer, .15M NaCL, 5% sucrose)
- filtered MillexHv13, .45 $\mu$ m
- 1.5mL applied
- 2.0mL (68 drops) fractions collected
- flow rate 0.42mL/min.
- column #1

Use of same originally administered Hyaluronan (Ha) as that used for determining molecular weight by Protein Standard in Figure 12A.

FIG. 12B

19/19




FIG. 13

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K31/715 A61K47/36 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| Y          | WO 95 26193 A (NORPHARMCO INC. ET AL.) 5<br>October 1995<br>cited in the application<br>see page 5, line 14 - line 30<br>see page 7, line 14 - page 8, line 26<br>---                                | 1-16                  |
| Y          | WO 91 04058 A (NORPHARMCO INC. ET AL.) 4<br>April 1991<br>cited in the application<br>see page 18, line 5<br>see page 26, line 32 - line 37<br>---   | 1-16                  |
| X          | WO 93 23059 A (ELF SANOFI ET AL.) 25<br>November 1993<br>see page 8, line 19 - line 27<br>see page 8, line 36 - page 9, line 2<br>see page 13, line 1 - line 24<br>see claims 1,5,8,9,12,13<br>----- | 1-16                  |

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

26 March 1997

Date of mailing of the international search report

16.04.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Alvarez Alvarez, C

# INTERNATIONAL SEARCH REPORT

national application No.

PCT/CA 97/00007

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 17-34  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO 9526193 A                              | 05-10-95            | AU 6422294 A               | 17-10-95            |
|   |                     | WO 9407505 A               | 14-04-94            |
|   |                     | WO 9529683 A               | 09-11-95            |
|   |                     | WO 9530423 A               | 16-11-95            |
|   |                     | WO 9606622 A               | 07-03-96            |
| -----                                     |                     |                            |                     |
| WO 9104058 A                              | 04-04-91            | AP 175 A                   | 03-04-92            |
|   |                     | AT 131068 T                | 15-12-95            |
|   |                     | AU 674894 B                | 16-01-97            |
|   |                     | AU 5227493 A               | 03-03-94            |
|   |                     | AU 6433090 A               | 18-04-91            |
|   |                     | CA 2042034 A               | 22-03-91            |
|   |                     | CN 1051503 A               | 22-05-91            |
|   |                     | DE 69024039 D              | 18-01-96            |
|   |                     | DE 69024039 T              | 13-06-96            |
|   |                     | EP 0445255 A               | 11-09-91            |
|   |                     | EP 0656213 A               | 07-06-95            |
|   |                     | ES 2080837 T               | 16-02-96            |
|   |                     | HU 64699 A                 | 28-02-94            |
|   |                     | HU 9500656 A               | 28-11-95            |
|   |                     | JP 4504579 T               | 13-08-92            |
|   |                     | LT 1582 A,B                | 26-06-95            |
| -----                                     |                     |                            |                     |
| WO 9323059 A                              | 25-11-93            | FR 2691066 A               | 19-11-93            |
|   |                     | EP 0641213 A               | 08-03-95            |
|   |                     | JP 7506584 T               | 20-07-95            |
| -----                                     |                     |                            |                     |